Our results provide novel insight into the pathogenesis of ABR dysfunction-induced neuroinflammation and suggest that targeting platelet CD40L is beneficial for the treatment of CNS disorders associated with ABR dysfunction. Here, CD40LG is linked to central nervous system disorder.